James Shannon
Chairman at MANNKIND CORPORATION
Net worth: 251 717 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Theresa Heggie | F | 63 | 1 years | |
| Ronald H. P. Brus | M | 61 |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | 12 years |
| Domenico Valerio | M | 67 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | 12 years |
| Gerard J. Platenburg | M | 60 | 12 years | |
| Kent Kresa | M | 86 | 20 years | |
| Daniel de Boer | M | 41 | 12 years | |
| René Beukema | M | 60 | 8 years | |
| Michael Castagna | M | 47 | 8 years | |
| Rosabel Realica Alinaya | F | 63 | 21 years | |
| Steven Binder | M | 61 | 7 years | |
| Jaap Goudsmit | M | 73 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
| David Thomson | M | 57 | 22 years | |
| Stephen L. Bandak | M | 74 |
The Royal College of Physicians
| 47 years |
| Peter Richardson | M | 64 |
The Royal College of Physicians
| 8 years |
| Sabrina Kay | M | 61 | 4 years | |
| Michael Friedman | M | 80 | 21 years | |
| Jennifer Grancio | F | 52 | 4 years | |
| Bart Filius | M | 53 | 5 years | |
| Alison Lawton | F | 62 | 10 years | |
| Sheila Sponselee | F | - | 4 years | |
| Koenraad Wiedhaup | M | - |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
| Christine Mundkur | F | 55 | 6 years | |
| Ronald Consiglio | M | 80 | 21 years | |
| Anthony Hooper | M | 69 | 4 years | |
| Pyarelal Baburam Tiwari | M | 77 |
The Royal College of Physicians
| - |
| Lindsey Rolfe | M | 56 |
The Royal College of Physicians
| - |
| Suyash Prasad | M | 54 |
The Royal College of Physicians
| - |
| Marc Kaptein | M | - |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | - |
| Stuart Ungar | M | 80 |
The Royal College of Physicians
| - |
| Abdur Rahman Khan | M | 90 |
The Royal College of Physicians
| - |
| Kei Siong Khoo | M | 62 |
The Royal College of Physicians
| - |
| Andrew Richard Rut | M | 63 |
The Royal College of Physicians
| - |
| Sanjay Rajpara | M | - |
The Royal College of Physicians
| - |
| Mike Anderson | M | - |
The Royal College of Physicians
| - |
| Ka Shing Yan | M | 38 |
The Royal College of Physicians
| - |
| Joseph Kocinsky | M | 60 | 21 years | |
| Rupert Vessey | M | 59 |
The Royal College of Physicians
| - |
| Zaki Morad bin Mohamad Zaher | M | 74 |
The Royal College of Physicians
| - |
| Man Yung Cheng | M | 74 |
The Royal College of Physicians
| 44 years |
| Alexandra Sinclair | M | - |
The Royal College of Physicians
| - |
| Steve Knowles | M | - |
The Royal College of Physicians
| - |
| Rosh Dias | M | - |
The Royal College of Physicians
| - |
| Richard Philipson | M | 60 |
The Royal College of Physicians
| - |
| Govindsingh Chavda | M | 45 |
The Royal College of Physicians
| 16 years |
| Karen Atkin | M | 58 |
The Royal College of Physicians
| - |
| Essra Ridha | M | 41 |
The Royal College of Physicians
| - |
| Monica Shaw | M | 46 |
The Royal College of Physicians
| - |
| Ash Soman | M | - |
The Royal College of Physicians
| - |
| Arvind Balakrishna Kasaragod | M | - |
The Royal College of Physicians
| - |
| Ray Tallis | M | - |
The Royal College of Physicians
| - |
| Brian John O’Keeffe | M | - |
The Royal College of Physicians
| - |
| Warren Cooper | M | 71 |
The Royal College of Physicians
| - |
| Christopher Ball | M | - |
The Royal College of Physicians
| - |
| Yiu Nam Lau | M | 63 |
The Royal College of Physicians
| 37 years |
| Martin Edwards | M | 68 |
The Royal College of Physicians
| - |
| Patricia Smith | M | - |
The Royal College of Physicians
| 40 years |
| Herman Waldmann | M | - |
The Royal College of Physicians
| - |
| Kwok Yiu Wong | M | 65 |
The Royal College of Physicians
| 38 years |
| Roger A. Perrault | M | 87 |
The Royal College of Physicians
| 44 years |
| Henry Y. Pan | M | 77 |
The Royal College of Physicians
| - |
| Helen Torley | M | 61 |
The Royal College of Physicians
| - |
| John Anderson | M | - |
The Royal College of Physicians
| - |
| Lesley Russell | M | 63 |
The Royal College of Physicians
| 37 years |
| Andrew Allen | M | 57 |
The Royal College of Physicians
| - |
| Adam Craig | M | 58 |
The Royal College of Physicians
| - |
| Frank Armstrong | M | 67 |
The Royal College of Physicians
| 40 years |
| Colin Broom | M | 68 |
The Royal College of Physicians
| - |
| Michael McDonald | M | - |
The Royal College of Physicians
| - |
| Richard Fuller | M | - |
The Royal College of Physicians
| - |
| Harry Solomon | M | 87 |
The Royal College of Physicians
| - |
| Charles Q. Morris | M | 59 |
The Royal College of Physicians
| - |
| Stephen D. Wise | M | - |
The Royal College of Physicians
| - |
| Athasit Vejjajiva | M | 88 |
The Royal College of Physicians
| - |
| Chee Siong Soo | M | 63 |
The Royal College of Physicians
| - |
| Peter Gardiner | M | - |
The Royal College of Physicians
| - |
| Kim Chan Koh | M | - |
The Royal College of Physicians
| - |
| Lewis J. Rubin | M | - |
The Royal College of Physicians
| - |
| Paul Kenna | M | - |
The Royal College of Physicians
| - |
| Kim Heung Tan | M | 62 |
The Royal College of Physicians
| 35 years |
| Alan Suggett | M | 80 |
The Royal College of Physicians
| - |
| Chrisantha Nicholas Nonis | M | - |
The Royal College of Physicians
| - |
| Emmet B. Keeffe | M | - |
The Royal College of Physicians
| - |
| Emiko Terasaki | M | - |
The Royal College of Physicians
| 25 years |
| Dawn Viveash | M | 68 |
The Royal College of Physicians
| - |
| Leo Kearns | M | - |
The Royal College of Physicians
| - |
| Stephen Lockhart | M | 67 |
The Royal College of Physicians
| 41 years |
| Kemal Malik | M | 61 |
The Royal College of Physicians
| - |
| Marnix Ploeg van der | M | - |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alfred Mann | M | 98 | 25 years | |
| Paul Sekhri | M | 65 |
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA.
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | 5 years |
| William Burns | M | 76 |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | 6 years |
| Hakan S. Edstrom | M | 74 | 14 years | |
| Matthew Pfeffer | M | 67 | 9 years | |
| Barry Moze | M | 70 | 8 years | |
| Henri A. Termeer | M | 78 | 5 years | |
| Duane DeSisto | M | 69 | 1 years | |
| Thomas Taapken | M | 59 | 3 years | |
| Philip Hampton | M | 70 | 4 years | |
| Beth Taylor | F | 59 | 8 years | |
| Stevenson Ward | M | 78 |
Sterling Winthrop, Inc.
 Sterling Winthrop, Inc. Electronics/AppliancesConsumer Durables Part of GSK Plc, Sterling Winthrop, Inc. is a private company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million. | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 64 | 64.00% |
| United States | 20 | 20.00% |
| Netherlands | 15 | 15.00% |
| Finland | 3 | 3.00% |
| Switzerland | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Shannon
- Personal Network